Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.96 -0.64 (-1.07%)
Streaming Delayed Price Updated: 2:15 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Via The Motley Fool
Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City
Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape. 
Via Benzinga
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
2 High-Yield Dividend Stocks to Buy Early in 2025
Via The Motley Fool
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
From Bristol Myers Squibb
Via Business Wire
Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential.
Investors are keeping a close eye on BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout. 
Via Chartmill
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Bristol Myers Squibb Stock Earns 83 RS Rating
On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. 
Via Investor's Business Daily
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
Via The Motley Fool
Topics ETFs
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 16-20, 2024. 
Via Talk Markets
Topics Stocks / Equities
Want Decades of Passive Income? 3 Stocks to Buy Right Now
Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills. 
Via The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
Via The Motley Fool
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
From Bristol Myers Squibb
Via Business Wire
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
Via The Motley Fool
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation
HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties and pricing agreement termination. 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook
Bristol-Myers Squibb Inc. (NYSE: BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.